Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OU7P
|
|||
| Former ID |
DNC001339
|
|||
| Drug Name |
SKF 38393
|
|||
| Synonyms |
SKF-38393; F-38393; 67287-49-4; F 38393; SKF38393; BRN 1543419; CHEMBL286080; 1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol; 2,3,4,5-Tetrahydro-1-phenyl-1H-3-benzazepine-7,8-diol; 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; SKF-38,393; SK-38393; C16H17NO2; 5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 1-Phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Terminated | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H17NO2
|
|||
| Canonical SMILES |
C1CNCC(C2=CC(=C(C=C21)O)O)C3=CC=CC=C3
|
|||
| InChI |
1S/C16H17NO2/c18-15-8-12-6-7-17-10-14(13(12)9-16(15)19)11-4-2-1-3-5-11/h1-5,8-9,14,17-19H,6-7,10H2
|
|||
| InChIKey |
JUDKOGFHZYMDMF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 67287-49-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6607884, 7980603, 8151056, 12013073, 14847852, 24439587, 26612740, 26747137, 26751970, 47365415, 47810976, 47810977, 47959975, 48035350, 48259459, 49877950, 50104645, 53787894, 57320837, 77323032, 85209305, 85788760, 90340892, 103102085, 103209798, 103918470, 104297170, 117616123, 124749714, 124879803, 124879804, 124879805, 126407030, 128328006, 134338871, 134340537, 135008800, 135651048, 137010202, 140305604, 162223778, 162884055, 179231005, 179578147, 226787234
|
|||
| ChEBI ID |
CHEBI:110200
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D1 receptor (D1R) | Target Info | Modulator | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Dopaminergic synapse | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Morphine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Dopamine receptor mediated signaling pathway | |||
| Pathwhiz Pathway | Dopamine Activation of Neurological Reward System | |||
| Reactome | Dopamine receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Hypothetical Network for Drug Addiction | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 935). | |||
| REF 2 | The D1 dopamine receptor agonist SKF-38393 stimulates the release of glutamate in the hippocampus. Neuroscience. 1999;94(4):1063-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.